Get the latest news, insights, and market updates on ETON (Eton Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Top Growth Companies With Strong Insider Ownership
As major U.S. stock indexes experience declines, particularly in the tech sector, and energy stocks outperform due to rising crude futures, investors are keenly observing market fluctuations and valuations. In this environment, growth companies with strong insider ownership can be appealing as they often signal confidence from those closest to the business. Sep 24, 2025 - $ETON
High Insider Ownership Growth Stocks To Watch In August 2025
In the wake of Federal Reserve Chair Jerome Powell's recent comments indicating potential interest rate cuts, U.S. markets have surged with the Dow Jones Industrial Average reaching a record high. This optimistic market environment highlights the importance of identifying growth companies with substantial insider ownership, as these stocks can offer unique insights into company confidence and potential resilience amidst shifting economic policies. Aug 22, 2025 - $ETON
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your Wells Fargo instituti Aug 20, 2025 - $ETON
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growthQ2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 millionLaunched KHINDIVI™ (hydrocortisone) Oral SolutionReached 100 active INCRELEX® patients, ahead of previous guidance of year endCompany projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous gu Aug 7, 2025 - $ETON
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In: (800) 715-9871 or (646) 307-1963; Conferenc Jul 28, 2025 - $ETON
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple